Overcoming Operational Challenges: How Intentional Planning Leads to Patient Diversity in Clinical Trials​

We’re bringing together leaders from throughout the biopharma industry to discuss what we can learn from real examples of progress in implementing more diversity in clinical trials.

Featuring panelists from the Association of Clinical Research Professionals (ACRP), Bristol Myers Squibb, Incyte Corporation and the NCI Community Oncology Research Program (NCORP).

Register Now

Missed the live webinar? You can also register to view the recording on demand.

Abstract:

How do we actually go about creating more equitable clinical trials? Join us for a discussion about how changing the way we operate and plan can lead to clinical trials that accurately represent our entire community. To succeed at this goal, we must ask ourselves: how do we go about overcoming the myth that inclusive/diverse trials can only be achieved through a quota system – and that the pursuit of more equitable trials subverts timelines? The second session in our four-part series, this active panel discussion with clinical operations leaders from throughout the biopharma industry will discuss how to achieve “a new normal,” with practical day-to-day solutions designed to drive adoption of patient diversity in clinical trials.

Moderator:

Nick Kenny, Chief Scientific Officer, Syneos Health

Over 21 years of experience in clinical development and consulting. Passionate about rapidly moving compelling new science for unmet medical needs through the development process to arrive at early and innovative decisions.
Nick has been with the company since 2006 where he grew and led the Oncology team until moving to the CSO role in 2018 where he oversees the Medical Team for Syneos Health, the Consortia Models for e.g. Rare Diseases and Cell and Gene Therapies and is a leader on Governance for our Dynamic Assembly of cutting edge data assets. Drives Thought Leadership for the company.
Senior representative to the Clinical Trials Transformation Initiative (CTTI) Steering Committee and Forum for Collaborative Research.
Early career in biomedical research in the UK, US and Canada. Faculty appointment at the University of Vermont Medical School for several years. Past experience in biopharma consulting.
Cancer survivor (Hodgkin's Lymphoma).
Board of Directors, Hospice of Wake County.